| (Values in U.S. Thousands) | Mar, 2022 | Mar, 2021 | Mar, 2020 | Mar, 2019 | Mar, 2018 |
| Sales | 230,970 | 59,320 | 0 | 0 | 0 |
| Sales Growth | +289.36% | unch | unch | unch | unch |
| Net Income | -205,980 | -255,130 | -288,990 | -273,550 | -143,260 |
| Net Income Growth | +19.26% | +11.72% | -5.64% | -90.95% | -71.69% |
Myovant Sciences Ltd (MYOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Fiscal Year End Date: 03/31